PrEPWatch is designed to be a clearinghouse for information on PrEP research (ongoing and completed; clinical trials and demonstration projects), data, additional research, cost, access and advocacy efforts across the globe.
PrEPWatch
Px Wire July-September 2022, Vol. 12, No. 2
PrEP Tracker data, preparing for new products, the HIV prevention pipeline and our prevention playlist. All that and more in the latest issue of Px Wire.
PEP Needs Some Pep! Addressing PEP Neglect in HIV Prevention Research, Programming and Uptake
Thursday, November 3, 2022
During this webinar, experts and advocates addressed why PEP has been long neglected in HIV prevention research, programming, and uptake.
Featuring Dr. James Ayieko, Dr. Julie Fox, Dr. Ken Mayer, Dr, Catherine Koss, Njambi Njuguna and Ace Robinson
Cost of Goods Sold (COGS) Analyses
FAQ Debrief
This FAQ explains the use of Cost of Good Sold Analyses (COGS) and how they inform planning for product introduction.
RINGing the Bell for Choice: Actions and Solutions on Dapivirine Ring Access
Thursday, September 22, 2022
Hear the latest updates from African advocates leading the advocacy for access to the dapivirine ring. Plus tune in for the Population Council’s plans for moving the ring forward on multiple fronts, from roll-out of the monthly ring to research around the 3-month ring and multipurpose ring.
Px Wire April-June 2022, Vol. 12, No. 1
Newly relaunched, PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research and development, implementation and advocacy. Download for a quick look at where we are in HIV prevention.
A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP (Summary)
AVAC published Translating Scientific Advance into Public Health Impact: A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP to provide a comprehensive view of all the moving parts and identify specific priority actions and actors responsible for ensuring time is not wasted and opportunity not squandered in introducing injectable cabotegravir for PrEP. ViiV, policy makers, normative agencies, donors, program implementers, researchers, generic manufacturers, civil society, advocates and communities each have critical roles to play in the coming months, and this summary provides an overview of the plan.
AVAC Comments to FDA in Support of PrEP Approval
Comments delivered to the FDA’s Antiviral Drugs Advisory Committee (AVDAC) Meeting by Mitchell Warren, Executive Director, AVAC.
Translating Scientific Advance into Public Health Impact
A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP
AVAC’s Plan for Accelerating Access and Introduction of Injectable CAB for PrEP provides a comprehensive view of all the moving parts involved in delivering this new PrEP option and identifies priorities for ensuring time is not wasted and opportunity is not squandered. The plan focuses on learning the lessons from the first ten years of delivering oral PrEP and how to move faster, more strategically, and with greater coordination to maximize the impact of injectable CAB for PrEP.
Statement on the Dapivirine Ring for Women: Call for Accelerated Global Access
This statement, from a coalition of advocates, applauds the WHO for its ongoing support and its 2021 recommendation of the dapivirine vaginal ring as an additional prevention option for women. The advocates call on funders, country governments and community leaders to sustain their support for the ring’s introduction and rollout in African countries where it is needed and for prompt regulatory reviews. And they call on HIV programs to integrate the ring, and collaborate with communities on the design of those programs.